新辅助化疗后残留孤立肿瘤细胞(ypN0i+)患者的淋巴结负荷与肿瘤学结局:OPBC-05/ICARO研究
该回顾性队列研究纳入18国62中心583例新辅助化疗后前哨淋巴结存在孤立肿瘤细胞的I–III期乳腺癌患者,182例(31%)接受腋窝淋巴结清扫、401例(69%)未接受。清扫组中30%发现额外阳性淋巴结但仅5%为大转移;3年任何腋窝复发率2%(95%CI 0.95–3.6),任何浸润性复发率11%(95%CI 8–14),不同腋窝手术方式间无统计学差异。
要点
- 新辅助化疗后前哨淋巴结孤立肿瘤细胞(ypN0i+)患者腋窝淋巴结负荷低,清扫组仅5%发现大转移。
- ypN0i+患者3年任何腋窝复发率为2%(95%CI 0.95–3.6),任何浸润性复发率为11%(95%CI 8–14)。
- 不同腋窝手术方式间3年腋窝复发与浸润性复发率无统计学差异,结果不支持对所有ypN0i+患者常规行腋窝淋巴结清扫。
核心结论
- ypN0(i+)患者腋窝淋巴结负荷低,经选择省略腋窝淋巴结清扫者腋窝复发罕见,结果不支持对所有ypN0(i+)患者常规行腋窝淋巴结清扫。
研究设计与样本
- Oncoplastic Breast Consortium-05/ICARO队列研究(ClinicalTrials.gov标识NCT06464341)回顾性分析18国62中心新辅助化疗后前哨淋巴结存在孤立肿瘤细胞的I–III期乳腺癌患者数据。
- 共纳入583例患者,182例(31%)接受补全性腋窝淋巴结清扫,401例(69%)未接受;中位年龄48岁。
- 主要终点为3年任何腋窝复发率,次要终点为任何浸润性复发率。
主要发现
- 74%患者诊断时临床淋巴结阳性,41%为激素受体阳性/人表皮生长因子受体2阴性肿瘤,前哨淋巴结含孤立肿瘤细胞的平均数为1.2个。
- 接受腋窝淋巴结清扫者更常见cN2/3期(17% vs 7%,P < .001)、冰冻切片检出孤立肿瘤细胞(62% vs 8%,P < .001)、淋巴血管侵犯(38% vs 24%,P < .001)、接受辅助胸壁放疗(89% vs 78%,P = .024)和淋巴结放疗(82% vs 75%,P = .038)。
- 腋窝淋巴结清扫组中30%发现额外阳性淋巴结,但仅5%为大转移。
- 3年任何腋窝复发率为2%(95%CI 0.95–3.6),任何浸润性复发率为11%(95%CI 8–14),不同腋窝手术方式间无统计学差异。
临床怎么用
- 原文结论指出,结果不支持对所有ypN0(i+)患者常规行腋窝淋巴结清扫。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The nodal burden of patients with residual isolated tumor cells (ITCs) in the sentinel lymph nodes (SLNs) after neoadjuvant chemotherapy (NAC) (ypN0i+) is unknown, and axillary management is not standardized. We investigated rates of additional positive lymph nodes (LNs) at axillary lymph node dissection (ALND) and oncologic outcomes in patients with ypN0i+ treated with and without ALND. METHODS: The Oncoplastic Breast Consortium-05/ICARO cohort study (ClinicalTrials.gov identifier: NCT06464341) retrospectively analyzed data from patients with stage I to III breast cancer with ITCs in SLNs after NAC from 62 centers in 18 countries. The primary end point was the 3-year rate of any axillary recurrence. The rate of any invasive recurrence was the secondary end point. RESULTS: In total, 583 patients were included, of whom 182 (31%) had completion ALND and 401 (69%) did not. The median age was 48 years. Most patients (74%) were clinically node-positive at diagnosis and 41% had hormone receptor-positive/human epidermal growth factor receptor 2-negative tumors. The mean number of SLNs with ITCs was 1.2. Patients treated with ALND were more likely to present with cN2/3 disease (17% v 7%, P < .001), have ITCs detected on frozen section (62% v 8%, P < .001), have lymphovascular invasion (38% v 24%, P < .001), and receive adjuvant chest wall (89% v 78%, P = .024) and nodal radiation (82% v 75%, P = .038). Additional positive nodes were found at ALND in 30% of patients, but only 5% had macrometastases. The 3-year rates of any axillary and any invasive recurrence were 2% (95% CI, 0.95 to 3.6) and 11% (95% CI, 8 to 14), respectively, with no statistical difference by type of axillary surgery. CONCLUSION: The nodal burden in patients with ypN0(i+) was low, and axillary recurrence after ALND omission was rare in patients selected for this approach. These results do not support routine ALND in all patients with ypN0(i+).
引用
- Montagna G, Laws A, Ferrucci M, et al. Nodal Burden and Oncologic Outcomes in Patients With Residual Isolated Tumor Cells After Neoadjuvant Chemotherapy (ypN0i+): The OPBC-05/ICARO Study. J Clin Oncol. 2024. PMID: 39509672. doi:10.1200/JCO.24.01052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。